Brockmann B, Geschke E, Schmidt U M, Ebeling K
Klinik und Poliklinik für Onkologie, Bereiches Medizin Charité, Humboldt-Universität zu Berlin.
Geburtshilfe Frauenheilkd. 1991 May;51(5):383-6. doi: 10.1055/s-2007-1026163.
Remission rates of 30-50% can be obtained using different cytostatic combinations in second line therapy of metastatic breast cancer. The combination of adriamycin and vincristin with cytostasan revealed a remission rate of 50% in 62 CMF-pretreated patients. Considerable toxic side effects led to a dose reduction of cytostasan and adriamycine in 43 patients without clinical efficacy loss. The long remission periods of the total responders (8-23 months) were remarkable. Both, 3 patients with bone +/- soft tissue metastasis and 4 patients with visceral metastasis benefited from a clinical total remission. The remission rates indicated no significant differences between the group of patients with soft tissue +/- bone metastasis (47.3%) and that with a predominantly visceral metastasis (50%). The CyAV-combination with a low dosage provides an effective therapeutical scheme with acceptable side effects for CMF-pretreated patients with breast cancer.
在转移性乳腺癌的二线治疗中，使用不同的细胞抑制剂组合可获得30%-50%的缓解率。阿霉素、长春新碱与环磷酰胺联合使用，在62例接受过CMF预处理的患者中缓解率达50%。43例患者出现明显的毒副作用，导致环磷酰胺和阿霉素剂量减少，但未影响临床疗效。所有缓解者的缓解期较长（8-23个月），这一点很显著。3例骨转移伴或不伴软组织转移患者以及4例内脏转移患者均实现了临床完全缓解。软组织伴或不伴骨转移患者组（47.3%）与主要为内脏转移患者组（50%）的缓解率无显著差异。低剂量的CyAV组合为接受过CMF预处理的乳腺癌患者提供了一种有效的治疗方案，且副作用可接受。
